Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Status:
Withdrawn
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This study evaluates the combination of BYL719, cisplatin and cetuximab as induction
chemotherapy prior to minimally-invasive transoral surgery (TORS or TLM) and selective lymph
node dissection (SLND), followed by risk-adapted intensity-modulated radiation therapy (IMRT)
in patients with transorally resectable, Stage III-IVa, HPV-associated oropharyngeal squamous
cell carcinoma (OPSCC).